A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease

NCT07220109 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

750

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus Infections

Interventions

BIOLOGICAL: RSVPreF3 OA vaccine
BIOLOGICAL: Placebo

Sponsor

GlaxoSmithKline